Evidence map›Paper›PMID 33953392›Full record

ArticleNature metabolism2021

Publisher Correction: Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation.

Jui-Hsia Weng, Peter David Koch, Harding H Luan, Ho-Chou Tu, Kenichi Shimada, Iris Ngan, Richard Ventura, Ruomu Jiang, Timothy J Mitchison

Open access · bronzeAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jui-Hsia WengDepartment of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. jui-hsia_weng@hms.harvard.edu.ORCID http://orcid.org/0000-0002-5878-3920
Peter David KochDepartment of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Harding H LuanNGM Biopharmaceuticals, South San Francisco, CA, USA.
Ho-Chou TuAlnylam Pharmaceuticals, Inc., Cambridge, MA, USA.
Kenichi ShimadaDepartment of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8540-9785
Iris NganNGM Biopharmaceuticals, South San Francisco, CA, USA.
Richard VenturaNGM Biopharmaceuticals, South San Francisco, CA, USA.
Ruomu JiangDepartment of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Timothy J MitchisonDepartment of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. timothy_mitchison@hms.harvard.edu.ORCID http://orcid.org/0000-0001-7781-1897
Harvard University · USNGM Biopharmaceuticals (United States) · USAlnylam Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s42255-021-00397-5.

Identifiers

PMID33953392
OpenAlexW3159266293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.